Neurology Xagena

Parkinson's disease associated with reduced risk of prostate cancer

Prostate cancer growth and progression may be linked to neurogenesis and to medical anti- Parkinson treatment, but results are inconclusive. Therefore, researchers have examined the association between Parkinson's disease and risk of prostate cancer in a population based case-control study.

45,429 patients diagnosed with incident prostate cancer during 1997-2010 from the National Cancer Registry were identified.
Five age-matched population controls ( n=227,145 ) were selected for each case.

The analyses were stratified by duration of Parkinson's disease and stage of prostate cancer ( localized and advanced ).

In total, 245 patients ( 0.5% ) and 1656 controls ( 0.7% ) had Parkinson's disease.

Overall, patients with Parkinson's disease had a 27% lower risk of prostate cancer compared with patients without Parkinson's disease ( adjusted OR, ORa=0.73; 95% confidence interval ( CI ), 0.63-0.83 ).

Risk of prostate cancer decreased with increasing duration of Parkinson's disease.

The odds ratios were slightly lower for advanced prostate cancer ( ORa=0.68; 95% CI, 0.52-0.88 ) than for localized prostate cancer ( ORa 0.76; 95% CI, 0.61-0.93 ).

In conclusion, Parkinson's disease was associated with a risk reduction overall ( 27% ), which decreased with increasing duration of Parkinson's disease. ( Xagena )

Jespersen CG et al, Cancer Epidemiol 2016;45:157-161